Glenmark Pharma Q2 revenue falls 30% to ₹4,247 crore, profit down 57%
Glenmark Pharmaceuticals moved lower in a quarterly results development for Q2FY27.
· BS Companies, Economic Times Markets, ET Stocks
Glenmark Pharmaceuticals' Q2FY27 net profit fell 56.8% to ₹263.83 crore, while revenue declined 29.8% to ₹4,247.32 crore, with earnings dragged by exceptional items.
Key facts
- Period
- Q2FY27
The analysis
Glenmark Pharmaceuticals reported ₹4,247 crore and ₹263.83 crore for Q2FY27, with movement of 30%, 57% and 56.8% attached to those lines. Those are the figures as filed — what moves the price is how they sit against what the market already expected, not their absolute size.
Against that, the stock is -0.9% on the day at ₹2,481.80, and has returned +9.9% over three months. It is trading close to its 52-week high, so expectations were already elevated going in. The pharma & healthcare sector has moved +1.1% over the same period, so Glenmark Pharmaceuticals is running 8.8 points ahead of its peers.
For Glenmark Pharmaceuticals, the question is how much of this is already reflected in the price and how much re-rates the pharma & healthcare peer set alongside it.
Why it matters
- Earnings versus expectations is what actually re-rates a stock; the surprise matters more than the absolute number.
Market context
- In focus: Glenmark Pharmaceuticals (GLENMARK), in Pharma & Healthcare.
- Over three months: Glenmark Pharmaceuticals +9.9% against Pharma & Healthcare +1.1% (8.8 points ahead).
| Company | Price | Day | 1M | 3M | From 52-wk high | Volume vs 20-day | Market cap |
|---|---|---|---|---|---|---|---|
| Glenmark PharmaceuticalsGLENMARK · Pharma & Healthcare | ₹2,481.80 | -0.9% | +8.1% | +9.9% | -1.3% | 1.4× | — |
Pharma & Healthcare
1M +3.9% · 3M +1.1%
Glenmark Pharmaceuticals
Prices as of 5 Nov 2026, 16:11 IST. Sector moves are the average of the stocks we track in each sector.
In this story
Related coverage
Emcure Pharma shares jump 7% after Q2 profit rises 29% YoY to Rs 325 crore
Biocon share price rises nearly 6% despite 52% dip in Q2 profit
Apollo's Bangladesh patient revenue nears pre-crisis peak of ₹450 crore
Q2 Results Live Updates: LG Electronics, Bharti Airtel, Abbott India, Astral, Bharat Forge, Berger Paints, Emami, Fortis Healthcare Earnings In Focus
Biocon Q2 profit halves to ₹41 crore as delayed shipments weigh on margins